SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Akzo Nobel N.V. (AKZOF) trades at a trailing P/E of 16.2, forward P/E of 15.0. Trailing earnings yield is 6.18%, forward earnings yield 6.67%. PEG 0.95 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
- VALUE (85/100, Pass) — P/E is below market average (16.2); PEG ≤ 1.0 — Peter Lynch undervalued (0.95); earnings yield beats bond yields (6.18%).
- Forward P/E 15.0 (down from trailing 16.2) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 0.95 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
- Trailing Earnings Yield 6.18% — exceeds typical bond yields (~4.3%), making equity attractive vs fixed income. Forward yield improves to 6.67% as earnings recover.
Overall SharesGrow Score: 66/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
85/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — AKZOF
Valuation Multiples
P/E (TTM)16.2
Forward P/E15.0
PEG Ratio0.95
Forward PEG1.92
P/B Ratio0.00
P/S Ratio1.01
EV/EBITDA0.0
Per Share Data
EPS (TTM)$3.70
Forward EPS (Est.)$3.99
Book Value / Share$0.00
Revenue / Share$59.24
FCF / Share$0.00
Yields & Fair Value
Earnings Yield6.18%
Forward Earnings Yield6.67%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$4.33 |
$14.2B |
$970M |
6.8% |
| 2017 |
$3.70 |
$9.61B |
$832M |
8.7% |
| 2018 |
$29.33 |
$9.26B |
$6.67B |
72.1% |
| 2019 |
$2.42 |
$9.28B |
$539M |
5.8% |
| 2020 |
$3.28 |
$8.53B |
$630M |
7.4% |
| 2021 |
$4.46 |
$9.59B |
$829M |
8.6% |
| 2022 |
$2.01 |
$10.85B |
$352M |
3.2% |
| 2023 |
$2.58 |
$10.67B |
$442M |
4.1% |
| 2024 |
$3.16 |
$10.71B |
$542M |
5.1% |
| 2025 |
$3.70 |
$10.15B |
$634.76M |
6.3% |
